摘要
目的探讨临床上采用莫西沙星联合依替米星治疗耐多药肺结核患者的近期疗效。方法以95例2012年1月1日-2014年9月1日之间在该院接受治疗的耐多药肺结核患者为研究对象,采用回顾性方法分析,依据治疗手段的不同将其分为对照组(45例)和观察组(50例),前者采用的是常规抗结核治疗联合阿米卡星与左氧氟沙星治疗;后者采用的是常规抗结核治疗联合依替米星与莫西沙星治疗,观察并对比两组患者的用药不良反应发生率、近期治疗有效率与治疗四个月后每个月的痰菌转阴率。结果观察组和对照组在以上观察指标上差异显著,且具有统计学意义(P<0.05)。结论针对耐多药肺结核患者采用莫西沙星联合依替米星治疗,在近期成效上显著,不良反应率小,痰菌转阴率高,值得推广应用。
Objective To explore the short-term curative effect observation of Moxifloxacin and etimicin combined regimen in the treatment of multi-drug resistant pulmonary tuberculosisclinical.Methods 95 patients with multi drug resistant pulmonary tuberculosis in our hospitao from January First 2012 to Nov First 2014 were selected as the research object, by adopting the method of retrospective analysis, according to the different treatments of the divided into control group (45 cases) and observation group (50 cases), the former taken the routine anti-tuberculosis treatment with amikacin and levofloxacin therapy; the other group taken a routine anti-tuberculosis treatment combined for and moxifloxacin treatment, observe and compare two groups of the incidence rate of adverse drug reaction,recently the treatment efficiency,after four months treatment the sputum negative conversion rate of every month.Results Results the observation group and the control group significant difference on the above observation indexes, and statistically significant (P〈0.05).Conclusion For multi-drug resistant tuberculosis patients to use moxifloxacin combined for m star treatment, significantly in the recent results, less adverse reaction rate, high rate of sputum bacterium turns shade, is worthy of popularization and application.
出处
《中外医疗》
2015年第11期122-123,共2页
China & Foreign Medical Treatment
关键词
莫西沙星
依替米星
耐多药肺结核
疗效
Moxifloxacin
Etimicin
Multidrug-resistant tuberculosis
Efficacy